CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 7 enrolled
Drug / intervention
Mycophenolate mofetildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00333437
NCT00333437N/ACompleted
CompareCT.gov

Pulmonary Involvement in Scleroderma: Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients

University of California, San Francisco·interventional·Posted Jun 5, 2006·Updated Nov 13, 2013

In Brief

A clinical study evaluating Mycophenolate mofetil for Scleroderma, Systemic. Completed, enrolled 7 participants across 1 site.

Detailed Summary

Researchers from the Division of Pulmonary and Critical Care Medicine at University of California, San Francisco (UCSF) are conducting a study to evaluate whether mycophenolate mofetil (an immunosuppressive medication, trade named CellCept) is safe and effective for preventing the lung damage from scleroderma from getting worse.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsScleroderma, Systemic
CountriesUnited States
CollaboratorsRoche Pharma AG

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 5, 2006
Enrollment StartMay 1, 2006
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 20.1 years ago

Interventions

Mycophenolate mofetildrug